Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.47 |
| ▸ | AR | P10275 | 6/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16894268 | 0.73 | KIF11 (0.56) | KIF11ARCYP11B1CYP11B2PGR | |
| SCHEMBL2167740 | 0.72 | KIF11 (0.57) | KIF11ARCYP11B1CYP11B2PGR | |
| SCHEMBL25257701 | 0.72 | CYP11B2 (0.47) | ARCYP11B1CYP11B2 | |
| SCHEMBL30510146 | 0.72 | CYP11B2 (0.47) | ARCYP11B1CYP11B2 | |
| SCHEMBL27740293 | 0.71 | PDE2A (0.34) | ARPDE2A | |
| SCHEMBL3480548 | 0.70 | KIF11 (0.56) | KIF11ARCYP11B1CYP11B2PGR | |
| SCHEMBL3480811 | 0.70 | CYP11B1 (0.68) | KIF11ARCYP11B1CYP11B2 | |
| SCHEMBL23088100 | 0.70 | CYP2A6 (0.38) | AR | |
| SCHEMBL12650323 | 0.70 | KIF11 (0.51) | KIF11ARCYP11B1CYP11B2PGR | |
| SCHEMBL6780932 | 0.69 | KIF11 (0.55) | KIF11ARCYP11B1CYP11B2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105689-A1 | NOVEL 1,4- AND 1,5-DIARYLSUBSTITUTED 1,2,3-TRIAZOLES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100105689-A1 | NOVEL 1,4- AND 1,5-DIARYLSUBSTITUTED 1,2,3-TRIAZOLES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-04-29 | — | — | US | disclosed |
| WO-2008087178-A1 | NOVEL 1,4- AND 1,5-DIARYLSUBSTITUTED 1,2,3-TRIAZOLES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105689-A1 | NOVEL 1,4- AND 1,5-DIARYLSUBSTITUTED 1,2,3-TRIAZOLES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNN3, KCNN2 | KIF11 1089/4885AR 4405/4885CYP11B1 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.